A Phase 4 interventional study of cyclosporine or tacrolimus and sirolimus in Graft Rejection and Kidney Failure, sponsored by Wyeth is now a wholly owned subsidiary of Pfizer. Completed at 23 sites in 7 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2011-05-30.
Sponsored by Wyeth is now a wholly owned subsidiary of Pfizer (part of Pfizer) · Phase 4, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 16 studies testing sirolimus in Renal Insufficiency — none open to participants now, none under way, none of them phase 3. Sirolimus · Renal Insufficiency.
Among the 16 studies testing sirolimus in Renal Insufficiency, this one is the 4th largest by enrollment, is one of 3 that started in 2006, is one of 6 in phase 4, and was the 12th registered.
1,413 studies on the registry are indexed under Renal Insufficiency; 146 are open to participants now.
Browse Renal Insufficiency studies →None of the 16 studies testing sirolimus in Renal Insufficiency is open now. The open studies under Renal Insufficiency, anywhere →
Sirolimus: first FDA approval 1999 (RAPAMUNE), first EMA approval 2001. What it is approved for, and how studies give it, is on its page →
Of the 92 Renal Insufficiency studies recruiting now, 48 (52%) set no upper age limit and 19 (21%) stop at 75 or younger; 8 take children under 18; 15 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
16 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 5 · Phase 3 4 · Phase 4 6
First in 2000; this study’s year is marked. 3 started in 2006.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 121 is above the median of 40 across 1,061 interventional studies indexed under Renal Insufficiency.
Median enrollment 63 across the 16 interventional studies. Of the 16 that completed or were terminated, 6 (38%) have results posted.
This tab as a report to print or save as PDF → With an account.
8 of 16 have an industry lead sponsor. The 8 most frequent:
This study is registered under Wyeth is now a wholly owned subsidiary of Pfizer, one of the names counted as Pfizer. Under that name alone:
Wyeth is now a wholly owned subsidiary of Pfizer is the lead sponsor of 484 studies on the registry; none are open to participants now.
37 studies in Renal Insufficiency by Pfizer: 2 open now, 3 under way, none of them phase 3. Of 34 finished, 15 (44%) have results posted.
Among the 37 studies in Renal Insufficiency by Pfizer, this one is the 7th largest by enrollment of the 36 interventional ones that give a count, is one of 3 that started in 2006, is one of 8 in phase 4, and was the 12th registered.
Pfizer’s Renal Insufficiency studies by the year they started, since 2002.
None of the studies under way reaches primary completion within a year.
Among the 16 studies testing sirolimus in Renal Insufficiency, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Pfizer’s 37 in Renal Insufficiency:
This tab as a report to print or save as PDF → With an account.
The primary purpose of this study is to determine whether converting from calcineurin inhibitor (CNI) therapy to sirolimus therapy will be more effective than continuing calcineurin inhibitor therapy with respect to renal function in cardiac transplant recipients with mild to moderate renal dysfunction.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Group 1: Continuation of CNI regimen
Drug: cyclosporine or tacrolimus
Group 2: (CNI-Free) Conversion to SRL-based regimen
Drug: sirolimus
Drug pages: Cyclosporine · Tacrolimus
Cyclosporine and tacrolimus are provided by the sites and dosed to achieve a target trough level determined by the investigator; therefore, form, dosage, and frequency are site and patient specific. Duration should be 52 weeks on-therapy.
Also known as: Brand names for cyclosporine are Neoral®, Sandimmune®, and Gengraf®; brand names for tacrolimus are Prograf® and Adagraf™.
Oral (1 and 2 mg) tablets, dosing should be once daily to achieve a target trough level of 7- 15 ng/mL. Duration should be 52 weeks on-therapy.
Also known as: Rapamune®
Change From Baseline in Calculated Creatinine Clearance (Cockcroft-Gault Equation) at 52 Weeks Post-randomization
Creatinine Clearance (CC) calculated using Cockcroft-Gault equation, adjusted for body surface area. Calculated CC: method to approximate kidney function. It measures rate creatinine (substance formed from metabolism of creatine) is cleared from blood by kidneys. Normal adult creatinine clearance is greater than or equal to (≥) 90 milliliters per minute per 1.73 meters squared (mL/min/1.73m\^2). Change from baseline=CC at Week 52 minus CC at baseline where higher scores represented improved renal function; Least squares mean adjusted for baseline calculated creatinine clearance and center.
Time frame: Baseline and Week 52
Calculated Creatinine Clearance (Cockcroft-Gault Equation) at Baseline
Creatinine clearance at baseline calculated using Cockcroft-Gault equation and adjusted for body surface area. Calculated CC: method to approximate kidney function. It measures rate creatinine (substance formed from metabolism of creatine) is cleared from blood by kidneys. Normal adult creatinine clearance is ≥ 90 mL/min/1.73m\^2.
Time frame: Baseline
Change From Baseline in Calculated Creatinine Clearance (Cockcroft-Gault Equation) at 4, 16, 24, 32, and 40 Weeks Post-randomization
Creatinine Clearance (CC) calculated using Cockcroft-Gault equation, adjusted for body surface area. Calculated CC: method to approximate kidney function. It measures rate creatinine (substance formed from metabolism of creatine) is cleared from blood by kidneys. Normal adult creatinine clearance is ≥ 90 mL/min/1.73m\^2. Change from baseline=CC at Week X minus CC at baseline where higher scores represented improved renal function; Least squares mean adjusted for baseline calculated creatinine clearance and center.
Time frame: Baseline and Weeks 4, 16, 24, 32, and 40
Change From Baseline in Calculated Creatinine Clearance (Modification of Diet in Renal Disease [MDRD] Equation) at 4, 16, 24, 32, 40 and 52 Weeks Post-randomization
Creatinine clearance calculated using MDRD equation. Normal adult creatinine clearance is ≥ 90 mL/min/1.73m\^2. Change from baseline=CC at Week X minus CC at baseline where higher scores represented improved renal function. Least squares mean adjusted for baseline calculated creatinine clearance (MDRD) and center.
Time frame: Baseline and Weeks 4, 16, 24, 32, 40 and 52
Calculated Creatinine Clearance (Modification of Diet in Renal Disease [MDRD] Equation) at Baseline
Creatinine clearance calculated using MDRD equation. Calculated CC: method to approximate kidney function. It measures rate creatinine (substance formed from metabolism of creatine) is cleared from blood by kidneys. Normal adult creatinine clearance is ≥ 90 mL/min/1.73m\^2.
Time frame: Baseline
Change From Baseline in Serum Creatinine Level at 4, 16, 24, 32, 40, and 52 Weeks Post-randomization
Serum creatinine is an indicator of kidney function. Creatinine is a substance formed from the metabolism of creatine, commonly found in blood, urine, and muscle tissue. It is removed from the blood by the kidneys and excreted in urine. Normal adult blood levels of creatinine=45 to 90 micromoles per liter (mcmol/L) for females, 60 to 110 mcmol/L for males, however normal values are age-dependent. Change from baseline=creatinine level at Week x minus baseline level where higher scores represented decreased kidney function. Least squares mean adjusted for treatment group and center.
Time frame: Baseline and Weeks 4, 16, 24, 32, 40, and 52
Serum Creatinine Level at Baseline
Serum creatinine is an indicator of kidney function. Creatinine is a substance formed from the metabolism of creatine, commonly found in blood, urine, and muscle tissue. It is removed from the blood by the kidneys and excreted in urine.
Time frame: Baseline
Annual Change in Calculated Creatinine Clearance (Cockcroft-Gault Equation)
The change in creatinine clearance over time assessed using the random coefficient slope of the regression line with creatinine clearance as the dependent variable and study day as the independent variable. Time points calculated as study days, relative to time of randomization of study medication. Observed data multiplied by a scale factor of 365 to express an annual change.
Time frame: Baseline to discontinuation (up to Week 52)
Overall Survival (OS)
Survival time from the start of study treatment to date of death due to any cause, censored at the last visit if no death. Death was determined from the Death report. The distribution of time to death was to be estimated using Kaplan-Meier method and compared between treatment groups with a proportional hazard model. The number and percent of survival at 6 and 12 months were to be reported.
Time frame: Baseline until death (up to Week 56)
Number of Participants With Acute Rejection
Based on International Society for Heart and Lung Transplantation \[ISHLT\] 1990 criteria: rejections Grade 3A or higher, rejection accompanied by hemodynamic compromise or requiring treatment. Grade 3A or higher included: multifocal aggressive infiltrates and/or myocyte damage, diffuse inflammatory process with necrosis, diffuse aggressive polymorphus with necrosis, increased infiltrates, and changes in edema, hemorrhage, or vasculitis. Biopsies performed for clinically suspected rejection (for cause), site's standard of care (site protocol biopsy), or protocol mandated.
Time frame: Baseline to Week 52
Number of Participants With Biopsy-confirmed Acute Rejection by Severity
Severity of acute rejection summarized using revised 2005 ISHLT criteria. Grade 0R: no rejection, Grade 1R: Focal (perivascular or interstitial) infiltrate without necrosis, diffuse but sparse infiltrate without necrosis, or one focus only with aggressive infiltration and/or focal myocyte damage, Grade 2R:Multifocal aggressive infiltrates and/or myocyte damage, and Grade 3R:Diffuse inflammatory process with necrosis, or diffuse aggressive polymorphous with necrosis, increased infiltrate, changes in edema, hemorrhage and vasculitis.
Time frame: Baseline to Week 52
Time to First Acute Rejection
Time from baseline to first biopsy-confirmed acute rejection defined as any of the following (based on ISHLT 1990 criteria): all rejections Grade 3A or higher, any rejection accompanied by hemodynamic compromise, or any rejection requiring treatment. ISHLT Grade 3A or higher included: Multifocal aggressive infiltrates and/or myocyte damage, diffuse inflammatory process with necrosis, diffuse aggressive polymorphus with necrosis, increased infiltrates, and changes in edema, hemorrhage, or vasculitis.
Time frame: Baseline to Week 52
Number of Participants Requiring Antibody Use in Treatment of Acute Rejection
Number of participants requiring antilymphocyte antibody therapy with suspected or biopsy-proven, steroid-resistant, acute rejection with or without hemodynamic compromise. Acute rejection based on ISHLT 1990 criteria: all rejections Grade 3A or higher, any rejection accompanied by hemodynamic compromise, or any rejection requiring treatment. ISHLT Grade 3A or higher included: Multifocal aggressive infiltrates and/or myocyte damage, diffuse inflammatory process with necrosis, diffuse aggressive polymorphus with necrosis, increased infiltrates, and changes in edema, hemorrhage, or vasculitis.
Time frame: Baseline to Week 52
Number of Participants in Sirolimus Treatment Group Requiring Conversion Back to CNI Therapy
Time frame: Baseline up to Week 52
Actual number of participants randomized was 121; however 5 participants randomized in error. They were withdrawn from study as screen failures, not administered study drug. Participants randomized (121) lower than planned (200); more sites added, time period to enroll extended twice up to 2.5 years. Despite this, final enrollment below planned.
| Milestone | Cyclosporine or Tacrolimus | Sirolimus (SRL) |
|---|---|---|
| Started | 59 | 57 |
| Received treatment | 57 | 57 |
| Completed assigned treatment regimen | 48 | 33 |
| Completed | 49 | 54 |
| Not completed | 10 | 3 |
| Withdrew: Death | 0 | 2 |
| Withdrew: Physician decision | 2 | 1 |
| Withdrew: Withdrawal by subject | 5 | 0 |
| Withdrew: Randomized, not treated | 2 | 0 |
| Withdrew: Other | 1 | 0 |
Creatinine Clearance (CC) calculated using Cockcroft-Gault equation, adjusted for body surface area. Calculated CC: method to approximate kidney function. It measures rate creatinine (substance formed from metabolism of creatine) is cleared from blood by kidneys. Normal adult creatinine clearance is greater than or equal to (≥) 90 milliliters per minute per 1.73 meters squared (mL/min/1.73m\^2). Change from baseline=CC at Week 52 minus CC at baseline where higher scores represented improved renal function; Least squares mean adjusted for baseline calculated creatinine clearance and center.
| mL/min/1.73m^2 | Cyclosporine or Tacrolimus | Sirolimus (SRL) |
|---|---|---|
| Change From Baseline in Calculated Creatinine Clearance (Cockcroft-Gault Equation) at 52 Weeks Post-randomization | -1.35 ± 1.18 | 3.03 ± 1.29 |
Creatinine clearance at baseline calculated using Cockcroft-Gault equation and adjusted for body surface area. Calculated CC: method to approximate kidney function. It measures rate creatinine (substance formed from metabolism of creatine) is cleared from blood by kidneys. Normal adult creatinine clearance is ≥ 90 mL/min/1.73m\^2.
| mL/min/1.73m^2 | Cyclosporine or Tacrolimus | Sirolimus (SRL) |
|---|---|---|
| Calculated Creatinine Clearance (Cockcroft-Gault Equation) at Baseline | 57.09 ± 11.96 | 57.75 ± 14.04 |
Creatinine Clearance (CC) calculated using Cockcroft-Gault equation, adjusted for body surface area. Calculated CC: method to approximate kidney function. It measures rate creatinine (substance formed from metabolism of creatine) is cleared from blood by kidneys. Normal adult creatinine clearance is ≥ 90 mL/min/1.73m\^2. Change from baseline=CC at Week X minus CC at baseline where higher scores represented improved renal function; Least squares mean adjusted for baseline calculated creatinine clearance and center.
| mL/min/1.73m^2 | Cyclosporine or Tacrolimus | Sirolimus (SRL) |
|---|---|---|
| Week 4 | -0.20 ± 1.06 | 2.96 ± 1.16 |
| Week 16 | -2.16 ± 1.37 | 3.79 ± 1.50 |
| Week 24 | -1.91 ± 1.28 | 2.15 ± 1.40 |
| Week 32 | -0.76 ± 1.32 | 2.22 ± 1.45 |
| Week 40 | 0.34 ± 1.39 | 2.70 ± 1.52 |
Creatinine clearance calculated using MDRD equation. Normal adult creatinine clearance is ≥ 90 mL/min/1.73m\^2. Change from baseline=CC at Week X minus CC at baseline where higher scores represented improved renal function. Least squares mean adjusted for baseline calculated creatinine clearance (MDRD) and center.
| mL/min/1.73m^2 | Cyclosporine or Tacrolimus | Sirolimus (SRL) |
|---|---|---|
| Week 4 | -0.00 ± 1.16 | 3.18 ± 1.25 |
| Week 16 | -1.92 ± 1.40 | 4.30 ± 1.51 |
| Week 24 | -1.47 ± 1.36 | 2.54 ± 1.47 |
| Week 32 | -0.15 ± 1.43 | 2.44 ± 1.54 |
| Week 40 | 0.69 ± 1.52 | 2.69 ± 1.64 |
| Week 52 | -0.90 ± 1.26 | 3.26 ± 1.36 |
Creatinine clearance calculated using MDRD equation. Calculated CC: method to approximate kidney function. It measures rate creatinine (substance formed from metabolism of creatine) is cleared from blood by kidneys. Normal adult creatinine clearance is ≥ 90 mL/min/1.73m\^2.
| mL/min/1.73m^2 | Cyclosporine or Tacrolimus | Sirolimus (SRL) |
|---|---|---|
| Calculated Creatinine Clearance (Modification of Diet in Renal Disease [MDRD] Equation) at Baseline | 55.39 ± 12.84 | 54.47 ± 14.14 |
Serum creatinine is an indicator of kidney function. Creatinine is a substance formed from the metabolism of creatine, commonly found in blood, urine, and muscle tissue. It is removed from the blood by the kidneys and excreted in urine. Normal adult blood levels of creatinine=45 to 90 micromoles per liter (mcmol/L) for females, 60 to 110 mcmol/L for males, however normal values are age-dependent. Change from baseline=creatinine level at Week x minus baseline level where higher scores represented decreased kidney function. Least squares mean adjusted for treatment group and center.
| mcmol/L | Cyclosporine or Tacrolimus | Sirolimus (SRL) |
|---|---|---|
| Week 4 | 1.68 ± 2.00 | -4.95 ± 2.15 |
| Week 16 | 7.96 ± 2.62 | -5.52 ± 2.82 |
| Week 24 | 8.02 ± 2.21 | -0.89 ± 2.37 |
| Week 32 | 4.08 ± 2.52 | -2.80 ± 2.71 |
| Week 40 | 2.44 ± 2.70 | 2.81 ± 2.90 |
| Week 52 | 4.76 ± 2.22 | -4.39 ± 2.39 |
Serum creatinine is an indicator of kidney function. Creatinine is a substance formed from the metabolism of creatine, commonly found in blood, urine, and muscle tissue. It is removed from the blood by the kidneys and excreted in urine.
| mcmol/L | Cyclosporine or Tacrolimus | Sirolimus (SRL) |
|---|---|---|
| Serum Creatinine Level at Baseline | 125.42 ± 23.15 | 126.21 ± 29.63 |
The change in creatinine clearance over time assessed using the random coefficient slope of the regression line with creatinine clearance as the dependent variable and study day as the independent variable. Time points calculated as study days, relative to time of randomization of study medication. Observed data multiplied by a scale factor of 365 to express an annual change.
| mL/min/1.73m^2 | Cyclosporine or Tacrolimus | Sirolimus (SRL) |
|---|---|---|
| Annual Change in Calculated Creatinine Clearance (Cockcroft-Gault Equation) | -0.740 (-2.921 to 1.441) | 1.571 (-0.447 to 3.588) |
Survival time from the start of study treatment to date of death due to any cause, censored at the last visit if no death. Death was determined from the Death report. The distribution of time to death was to be estimated using Kaplan-Meier method and compared between treatment groups with a proportional hazard model. The number and percent of survival at 6 and 12 months were to be reported.
No measurements were reported for this outcome.
Based on International Society for Heart and Lung Transplantation \[ISHLT\] 1990 criteria: rejections Grade 3A or higher, rejection accompanied by hemodynamic compromise or requiring treatment. Grade 3A or higher included: multifocal aggressive infiltrates and/or myocyte damage, diffuse inflammatory process with necrosis, diffuse aggressive polymorphus with necrosis, increased infiltrates, and changes in edema, hemorrhage, or vasculitis. Biopsies performed for clinically suspected rejection (for cause), site's standard of care (site protocol biopsy), or protocol mandated.
| Participants | Cyclosporine or Tacrolimus | Sirolimus (SRL) |
|---|---|---|
| For cause biopsies (n=57, 57) | 1 | 5 |
| Standard of Care biopsies (n=11, 11) | 0 | 2 |
| Protocol mandated biopsies (n=0, 39) | NA | 7 |
Severity of acute rejection summarized using revised 2005 ISHLT criteria. Grade 0R: no rejection, Grade 1R: Focal (perivascular or interstitial) infiltrate without necrosis, diffuse but sparse infiltrate without necrosis, or one focus only with aggressive infiltration and/or focal myocyte damage, Grade 2R:Multifocal aggressive infiltrates and/or myocyte damage, and Grade 3R:Diffuse inflammatory process with necrosis, or diffuse aggressive polymorphous with necrosis, increased infiltrate, changes in edema, hemorrhage and vasculitis.
| Participants | Cyclosporine or Tacrolimus | Sirolimus (SRL) |
|---|---|---|
| Grade 0R protocol mandated | NA | 0 |
| Grade 0R for cause | 0 | 0 |
| Grade 0R site protocol | 0 | 0 |
| Grade 1R protocol mandated | NA | 0 |
| Grade 1R for cause | 0 | 0 |
| Grade 1R site protocol | 0 | 0 |
| Grade 2R protocol mandated | NA | 6 |
| Grade 2R for cause | 0 | 4 |
| Grade 2R site protocol | 0 | 1 |
| Grade 3R protocol mandated | NA | 1 |
| Grade 3R for cause | 1 | 1 |
| Grade 3R site protocol | 0 | 1 |
Time from baseline to first biopsy-confirmed acute rejection defined as any of the following (based on ISHLT 1990 criteria): all rejections Grade 3A or higher, any rejection accompanied by hemodynamic compromise, or any rejection requiring treatment. ISHLT Grade 3A or higher included: Multifocal aggressive infiltrates and/or myocyte damage, diffuse inflammatory process with necrosis, diffuse aggressive polymorphus with necrosis, increased infiltrates, and changes in edema, hemorrhage, or vasculitis.
No measurements were reported for this outcome.
Number of participants requiring antilymphocyte antibody therapy with suspected or biopsy-proven, steroid-resistant, acute rejection with or without hemodynamic compromise. Acute rejection based on ISHLT 1990 criteria: all rejections Grade 3A or higher, any rejection accompanied by hemodynamic compromise, or any rejection requiring treatment. ISHLT Grade 3A or higher included: Multifocal aggressive infiltrates and/or myocyte damage, diffuse inflammatory process with necrosis, diffuse aggressive polymorphus with necrosis, increased infiltrates, and changes in edema, hemorrhage, or vasculitis.
| Participants | Cyclosporine or Tacrolimus | Sirolimus (SRL) |
|---|---|---|
| Number of Participants Requiring Antibody Use in Treatment of Acute Rejection | 1 | 0 |
| Participants | Sirolimus (SRL) |
|---|---|
| Number of Participants in Sirolimus Treatment Group Requiring Conversion Back to CNI Therapy | 21 |
Collected over Baseline up to Week 56. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Cyclosporine or Tacrolimus | — | 13/57 (22.8%) | 40/57 (70.2%) |
| Sirolimus (SRL) | — | 30/57 (52.6%) | 54/57 (94.7%) |
| Event | Cyclosporine or Tacrolimus | Sirolimus (SRL) |
|---|---|---|
| Transplant rejectionGeneral disorders | 1/57 | 13/57 |
| PneumoniaRespiratory, thoracic and mediastinal disorders | 0/57 | 4/57 |
| MyalgiaMusculoskeletal and connective tissue disorders | 0/57 | 3/57 |
| Skin carcinomaSkin and subcutaneous tissue disorders | 3/57 | 2/57 |
| CholelithiasisGastrointestinal disorders | 2/57 | 0/57 |
| Upper respiratory infectionRespiratory, thoracic and mediastinal disorders | 1/57 | 2/57 |
| Abdominal painGeneral disorders | 1/57 | 1/57 |
| AstheniaGeneral disorders | 0/57 | 1/57 |
| FeverGeneral disorders | 0/57 | 1/57 |
| Lab test abnormalGeneral disorders | 1/57 | 0/57 |
| Event | Cyclosporine or Tacrolimus | Sirolimus (SRL) |
|---|---|---|
| Peripheral edemaMetabolism and nutrition disorders | 9/57 | 18/57 |
| RashSkin and subcutaneous tissue disorders | 2/57 | 16/57 |
| DiarrheaGastrointestinal disorders | 6/57 | 15/57 |
| Uterine fibroids enlargedRenal and urinary disorders | 1/5 | 0/12 |
| Uterine hemorrhageRenal and urinary disorders | 1/5 | 0/12 |
| Upper respiratory infectionRespiratory, thoracic and mediastinal disorders | 11/57 | 10/57 |
| HeadacheGeneral disorders | 2/57 | 8/57 |
| Aphthous stomatitisGastrointestinal disorders | 0/57 | 8/57 |
| AcneSkin and subcutaneous tissue disorders | 0/57 | 8/57 |
| Abdominal painGeneral disorders | 3/57 | 7/57 |
| Age Continuous(years) | Cyclosporine or Tacrolimus | Sirolimus (SRL) | Total |
|---|---|---|---|
| Mean | 58.93 ± 8.01 | 57.40 ± 9.42 | 58.18 ± 8.73 |
| Sex: Female, Male(Participants) | Cyclosporine or Tacrolimus | Sirolimus (SRL) | Total |
|---|---|---|---|
| Female | 5 | 12 | 17 |
| Male | 54 | 45 | 99 |
The record gives a start of Sep 2006, a primary completion of Apr 2010 and a completion of May 2010. It does not say whether these dates are actual or estimated.
Results were first posted in May 2011, 1 year 1 month after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2011. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Sirolimus
Wyeth is now a wholly owned subsidiary of Pfizer →